Kayo Miura

Juntendo University, Edo, Tōkyō, Japan

Are you Kayo Miura?

Claim your profile

Publications (15)10.05 Total impact

  • [Show abstract] [Hide abstract]
    ABSTRACT: It has been well known that habitual smoking accelerates premature skin ageing recognized as ‘smoker's face’. However, the effect of smoking cessation on the appearance of skin has not been elucidated. The aim of this study was to evaluate objectively the effect of smoking cessation on the skin's appearance. The stratum corneum carbonyl protein level and skin colour of the cheek and the hand were measured. The change before and during the smoking cessation treatment (0, 2, 4, 8 and 12 weeks), and the success or failure in smoking cessation, was compared and examined. Eighty-four cases who had smoking cessation treatment were examined. The level of the stratum corneum carbonyl protein did not show any difference comparing before and after treatment for the smoking cessation success group and the failure group. The lightness of skin colour showed an upward tendency 4–12 weeks after starting the treatment in the success group and increased significantly compared with the failure group. The redness showed a significant decrease in comparison with before the treatment, and it also showed a significant decrease compared with the failure group. The yellowness did not show any clear tendency. Also, the haemoglobin showed a decreased tendency. Furthermore, multivariate statistical analysis showed a possibility that the lightness and haemoglobin could be changed by smoking cessation treatment. In conclusion, our study showed that an upward tendency of skin lightness was seen to correspond with a haemoglobin decrease accompanied by smoking cessation. If we can easily measure skin improvement as an effect of smoking cessation, it is thought to be a useful aid for smoking cessation support. Il est bien connu que le tabagisme habituel accélère le vieillissement prématuré de la peau, reconnu comme “le visage du fumeur». Cependant, l'effet du sevrage tabagique sur l'apparencede la peau n'a pas été élucidé. Le but de cette étude était d'évaluer objectivement l'effet decessation du tabagisme sur l'apparence de la peau. La teneur du stratum corneum en protéines carbonylées et la couleur de peau de la joue et de la mainont été mesurées. Le changement, avant et pendant le traitement de désaccoutumance au tabac (0, 2, 4, 8, et12 semaines), et le succès ou l'échec dans le sevrage tabagique, ont été comparés et examinés.Quatre-vingt-quatre cas de fumeurs ayant suivi un traitement de désaccoutumance ont été examinés. Le niveau du degré de carbonylation des protéines de la couche cornée n'a pas montré de différence dans la comparaison avant et aprèstraitement entre le groupe ayant réussi le sevrage tabagique et le groupe d'échec. La blancheur de la couleur de la peau a montré une tendance à la hausse 4 ~ 12 semaines après le début du traitement dans le groupe ayant réussi et a augmenté de façon significative par rapport au groupe d'échec. La rougeur a montré unediminution significative par rapport au début, avant le traitement, et ce paramètre a également montré une importante diminution par rapport au groupe d'échec. Le jaune n'a montré aucune tendance claire.En outre, le taux d'hémoglobine a montré une tendance réduite. En outre, l'analyse statistique multivariantea indiqué la possibilité que la clarté et la couleur due à l'hémoglobine peuvent être modifiées par le traitement de désaccoutumance du tabagisme. En conclusion, notre étude a montré que la tendance à l'éclaircissement de la peau, concomitant à une diminution de l'hémoglobine visible accompagnaient l'arrêt du tabac. Si nous pouvonsfacilement mesurer l'amélioration de la peau comme un effet de sevrage tabagique, on peut le considérer comme unaide utile pour le soutien pendant le sevrage tabagique.
    International journal of cosmetic science 11/2012; 35(2). DOI:10.1111/ics.12025 · 1.38 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Objective: The effects of continuation of chemotherapy on the quality of life (QOL) of elderly patients with lung cancer have not yet been clearly demonstrated. The aim of this study was to clarify the QOL profiles in elderly patients during chemotherapy in comparison with younger patients. Patients: Forty-nine patients aged 65 and older (group A) who were undergoing chemotherapy for lung cancer and 36 patients younger than 65 (group B) in similar therapy were retrospectively analyzed. Methods: QOL and performance status (PS) were evaluated using the QOL-anticancer drugs (ACD) scale and Karnofsky performance status (KPS) scale at the beginning of each course of chemotherapy, respectively. The total score of each QOL domain and KPS at each course were compared between the groups. Results: No differences were observed in gender, histology, stage, KPS, applied chemotherapeutic regimen, response rate, or median survival between the groups. With regard to the hematological toxicity, greater than grade 3 or equal leukopenia and neutropenia were more frequently observed in group A. The total score of the functional domain was significantly deteriorated during chemotherapy in group A, while that in group B was not altered (p = 0.014 by repeated ANOVA). Interestingly, a moderate correlation between KPS and the total score of the functional QOL domain was observed (r = 0.454). Conclusions: Continuation of chemotherapy for elderly patients with lung cancer led to a marked deterioration in the functional QOL. The KPS can be useful for estimating the functional QOL in cases where QOL data is missing.
    01/2012; 58(6):506-511. DOI:10.14789/pjmj.58.506
  • [Show abstract] [Hide abstract]
    ABSTRACT: Although zoledronic acid (ZOL) has been reported to inhibit bone metastasis from lung cancer, the optimum chemotherapy regimen in combination with ZOL has not yet been determined. Eighteen patients having non-small cell lung cancer (NSCLC) with bone metastasis who received carboplatin/nedaplatin plus paclitaxel combined with ZOL (4 mg every 28 days) were enrolled to investigate the feasibility of this treatment. The efficacy was evaluated by the percentage of patients at 9 months who were receiving radiation therapy, the time to first radiation treatment, and quality of life. Adverse effects were also evaluated. Only 3 among 18 patients received radiation therapy for bone metastases during the 9 months of the study. ZOL seems to prolong the median time to the first radiation treatment and maintain the quality of life regarding pain and activity status. No patients discontinued the treatment, although grade 3 or 4 treatment-related adverse effects occurred in 8 patients. ZOL combined with carboplatin/nedaplatin plus paclitaxel is an effective and tolerable treatment for NSCLC with bone metastases.
    09/2011; 97(5):568-72. DOI:10.1700/989.10713
  • [Show abstract] [Hide abstract]
    ABSTRACT: The lung is one of the sites of granulomatous responses, which are characterized by the recruitment and organization of activated macrophages and lymphocytes. There have been several reports that have shown that some pulmonary granulomatous diseases, such as sarcoidosis and nontuberculous mycobacterial disease, are likely to be characterized by a preponderance in postmenopausal females. Although sex hormones have been shown to play an important role in the regulation of the immune system, the influence of sex hormones on pulmonary granuloma formation is still unclear. Objectives: The purpose of this study was to assess whether sex hormones are involved in granulomatous inflammation and to evaluate how sex hormones modulate this response in the lung. Ovariectomized rats were used as an experimental postmenopausal model in which chronic pulmonary granulomatous inflammation was induced by intravenous injection of complete Freund's adjuvant. Histological analysis of lung tissues demonstrated enhancement of granuloma formation in the ovariectomized group. Such enhanced granuloma formation was significantly associated with generalized Th1-biased cytokine production in the bronchoalveolar lavage fluid. These results indicate that sex hormones play an important role in pulmonary granuloma formation by altering the Th1 responses.
    Respiration 04/2011; 81(6):491-8. DOI:10.1159/000324295 · 2.59 Impact Factor
  • American Thoracic Society 2010 International Conference, May 14-19, 2010 • New Orleans; 05/2010
  • [Show abstract] [Hide abstract]
    ABSTRACT: The patient was 54-year-old woman diagnosed as recurrent invasive thymoma (type B3; WHO classification). Although partial response was obtained by systemic chemotherapy (PAC: cisplatin, doxorubicin, cyclophosphamide), the tumor started to become enlarged after cessation of chemotherapy. Combined treatment of octreotide and prednisolone was administrated because various chemotherapies, including PAC, were not effective. After seven months, the tumor size was markedly decreased. The combination of octreotide and prednisolone should be considered as one of the choices of treatment in patients with recurrent thymoma.
    Internal Medicine 02/2009; 48(12):1061-4. DOI:10.2169/internalmedicine.48.1922 · 0.90 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Gefitinib is a molecular targeting agent and more effective in patients with characteristics of oriental ethnicity, female gender, adenocarcinoma and non-smokers. It is sometimes effective in smokers, but few papers have focused on the association between efficacy and smoking history. The aim of this study is to evaluate the association between efficacy of gefitinib and patients' characteristics, especially smoking history. Between July 2002 and September 2006, 89 patients were diagnosed as non-small cell lung cancer and administered gefitinib. Eighty of them were assessable for efficacy and toxicity of gefitinib. Response rate was 16.2% and 39.6%(p=0.031)in smokers and non-smokers. Survival was statistically greater in non-smokers. In smokers, there are more cases which showed response to gefitinib with a lower smoking index and longer duration after smoking cessation. Smoking index and duration after smoking cessation should be considered when gefitinib is administered or EGFR mutation analysis is conducted in patients with non-small cell lung cancer.
    Gan to kagaku ryoho. Cancer & chemotherapy 01/2009; 35(13):2367-71.
  • [Show abstract] [Hide abstract]
    ABSTRACT: A survival benefit of patients with inoperable non-small cell lung cancer has been reported since a development of new therapeutic agents in the 1990's. However, multivariate analyses of patients have not been evaluated. The aim of this study is to identify prognostic factors in the long-term survivors who had been treated with chemotherapy using these new agents and/or radiotherapy. A retrospective study and clinical analysis of 121 inoperable nonsmall cell lung cancer patients were conducted. Fifteen cases (male: 9, female: 6) with a survival of more than 2 years were revealed. Regarding clinical variables between the 15 cases and others, an early nodal (N) status, a high serum protein level, a good performance status (PS) and those having first-line chemotherapy or radiotherapy were all identified as significant prognostic factors for the long-term survivors. Multivariate analyses also revealed that an early N status, a good PS, female gender and chemotherapy and/or radiotherapy were associated with the long-term survivors. These results suggest that patients with inoperable non-small cell lung cancer should be considered for appropriate treatments including new chemotherapeutic agents.
    Gan to kagaku ryoho. Cancer & chemotherapy 12/2006; 33(11):1595-602.
  • [Show abstract] [Hide abstract]
    ABSTRACT: Various autoimmune diseases have been reported to occur in patients with sarcoidosis. However, coexistence of sarcoidosis and antiphospholipid syndrome (APS) is extremely rare. We describe a 59-year-old female patient with pulmonary sarcoidosis who had preceding APS. Her previous medical history consisted of a miscarriage and ischemic colitis. She was diagnosed as APS during the onset of a brainstem infarction with positive reaction to beta2-glycoprotein I-dependent anticardiolipin antibody. Two years later, chest CT revealed enlargement of the hilar and mediastinal lymph nodes and small nodules in the lung fields. Transbronchial lung biopsy demonstrated non-caseating epithelioid cell granuloma leading to the diagnosis of definite pulmonary sarcoidosis. This is the first APS case where pulmonary involvement with sarcoidosis has been confirmed through lung biopsy. Our case report suggests that APS should be recognized as an accompanying disorder of sarcoidosis.
    Respirology 08/2006; 11(4):506-8. DOI:10.1111/j.1440-1843.2006.00880.x · 3.35 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: A 51-year-old man underwent left upper lobectomy due to pulmonary adenocarcinoma (cT2N1M0, stage IIB) in August, 2003. Since he turned out pT2N3M0 stage IIIB, he received combination chemotherapy with carboplatin and gemcitabine. During a second course chemotherapy, he was admitted again because of dyspnea and the deterioration of diffuse interstitial shadows in both lungs. He was treated with various antibiotics and corticosteroids. Unfortunately, he could not recover. An autopsy was performed. Microscopic features of the lung revealed diffuse alveolar damage and pulmonary hemorrhage. In this case, pulmonary hemorrhage should be considered as a complication of gemcitabine-induced lung injury.
    04/2006; 44(3):215-9.
  • [Show abstract] [Hide abstract]
    ABSTRACT: わが国において肺癌は増加傾向にあり, また, 癌死の第1位であることから, その臨床的対応は急務である. 肺癌は組織学的に非小細胞肺癌Non-Small Cell Lung Cancer (NSCLC) と小細胞肺癌Small Cell Lung Cancer (SCLC) に分類され, その生物学的特性も異なる. 局所進展型のNSCLCの標準的治療は放射線と化学療法の同時併用であり, 遠隔転移を伴うNSCLCは全身状態Performance Status (PS) が許せば化学療法が第1選択となる. 1990年以降, パクリタキセル, ゲムシタビン, ドセタキセル, ビノレルビン, 塩酸イリノテカンなどの新規抗癌剤が導入され, 現在ではプラチナ製剤 (シスプラチンCisplatin (CDDP) あるいはカルボプラチンCarboplatin (CBDCA) ) と新規抗癌剤の2剤併用が進行NSCLCの標準的治療である. 高齢者はプラチナ製剤の使用が困難なことが多く, ビノレルビンあるいはドセタキセルの単剤投与も推奨されている. 初期治療に反応しない, あるいは再発症例に対してはドセタキセルの単独投与あるいはゲフィチニブ (イレッサ®) が選択される. ゲフィチニブはがん細胞表面に発現する上皮増殖因子受容体のチロシンキナーゼを特異的に阻害する小化合物であるがresponderとnon-responderがあること, 副作用としての5%の症例に急性肺障害が発症することが報告された. SCLCは早期から遠隔転移することが多く化学療法か放射線治療が適応となる. 限局型症例でPSが良好 (かつ高齢者でない) な症例では化学療法 (シスプラチンとエトポシド) と1日2回の多分割放射線照射の同時併用が選択される. 一方, 進展型の標準的治療は化学療法単独 (シスプラチンと塩酸イリノテカン) とである. これらの治療により, 手術不能肺がん症例の治療成績は飛躍的に向上し, NSCLC手術不能の1年生存率は20-30%に, SCLC LD症例は3年生存率30%となった. 高齢者に多い進行肺癌の治療は根治が困難であることから予後の改善とともにQuality of Life (QOL) を考慮した治療選択をすべきである.
    01/2006; 52(4):536-545. DOI:10.14789/pjmj.52.536
  • [Show abstract] [Hide abstract]
    ABSTRACT: We report an elderly case of sarcoidosis with multiple pulmonary cysts. An 80-year-old woman was admitted to our hospital for detailed examinations of multiple cysts in both lungs. Chest radiography and chest CT revealed multiple cystic lesions with thin walls which were clearly separated from normal lung. A transbronchial lung biopsy revealed epitheloid cell granuloma, indicating sarcoidosis. Although elderly cases of sarcoidosis with multiple pulmonary cysts are very rare, sarcoidosis should be considered in the differential diagnosis.
    07/2005; 43(6):370-4.
  • [Show abstract] [Hide abstract]
    ABSTRACT: We evaluated diagnosis and treatment of four cases of meningeal carcinomatosis associated with primary lung cancer: case 1; small cell carcinoma (64 years old), case 2; small cell carcinoma (50 years old), case 3; adenocarcinoma (53 years old), and case 4; adenocarcinoma (55 years old). Determination of tumor markers in cerebrospinal fluid (CSF) together with the MRI findings that Gd-DTPA-enhanced T1-weighted image showing high intensity signal along the spinal cord was clinically useful in the diagnosis of meningeal carcinomatosis. Two of four patients received intrathecal chemotherapy and/or CSF drainage through Ommaya-Reservoir, resulting in dramatic improvement of various symptoms such as motor weakness and vesicorectal disorder. Intrathecal chemotherapy and placement of an Ommaya-Reservoir for CSF drainage should be considered to provide better Quality of Life (QOL) when patient can tolerate it.
    04/2005; 43(3):139-43.
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Tenascin (Tn)-C is an extracellular matrix protein that is involved in tissue interactions during fetal development and oncogenesis. However, the role of serum Tn-C in non-small cell lung cancer (NSCLC) has not been clarified. In this study, we determined the serum levels of Tn-C among NSCLC patients who underwent surgery, as well as other factors implicated for angiogenesis, to address the clinical implications in NSCLC. The median concentration of serum Tn-C in NSCLC patients was slightly higher than that of normal controls, but this difference was not statistically significant. There was a positive correlation between serum Tn-C levels and microvessel density (MVD), serum osteopontin (OPN) and vascular endothelial growth factor (VEGF). In contrast, there was no correlation between serum Tn-C levels and serum carcinoembryonic antigen (CEA) and sialyl lewis-X (SLX) levels. The overall survival of patients with low Tn-C levels (<96 ng/ml) was significantly greater than that of patients with high Tn-C levels (> or =96 ng/ml). Intratumoral Tn-C expression was co-localized with expression of microvessels in the stroma of the cancer cells by immunohistochemical analysis. Moreover, enhanced in vitro migration of human umbilical vascular endothelial cells (HUVEC) was induced by recombinant Tn-C. Collectively, Tn-C may play an important role in angiogenesis of patients with NSCLC, and the determination of serum Tn-C may be useful in predicting intratumoral vasculature and patients' prognosis.
    Anticancer research 01/2005; 25(1B):489-95. · 1.83 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Sarcoidosis is a systemic granulomatous disease that affects various organs. However, its pathogenesis has not yet been fully understood. Biochemical markers in sarcoidosis appears to be closely related to the immunological events and the activity of inflammatory effector cells at sites of granuloma. These markers, therefore, have been expected to reflect the disease activity and/or to predict prognosis. Although some markers are helpful tools as diagnostic aids and disease activity markers, no single marker allows definitive diagnosis of sarcoidosis or may accurately predict the disease prognosis. Among numerous biochemical markers reported previously, only angiotensin converting enzyme (ACE) serum level has gained a proven value in the clinical field. Further studies are required to identify more useful biochemical markers, which allow definitive diagnosis or predict the disease activity and prognosis in sarcoidosis.
    Nippon rinsho. Japanese journal of clinical medicine 10/2002; 60(9):1741-6.